Beyond Bariatric Surgery: Retatrutide and the 30% Weight Loss Frontier 🚀

from Dr RR Baliga's "Got Knowledge Doc" Podkast · host MasterMedFacts LLC

⚖️🚀 RETATRUTIDE may redefine obesity medicine. In the Phase 3 TRIUMPH-1 trial, Lilly's triple agonist (GIP/GLP-1/glucagon) achieved an astonishing 28.3% average weight loss at 80 weeks, with some patients exceeding 30% weight reduction — territory once associated mainly with bariatric surgery. 📉 Even the 4 mg dose achieved nearly 20% weight loss with fewer discontinuations. Significant improvements were also seen in waist circumference, triglycerides, systolic BP, and hsCRP. ❤️ A fascinating glimpse into the future of cardiometabolic therapeutics. 🎙️ Dr RR Baliga's Podkast for the Kurious Doc #Obesity #Retatrutide #GLP1 #Cardiology #Endocrinology #WeightLoss #Medical

Episode metadata supplied by the publisher feed · Published May 25, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Beyond Bariatric Surgery: Retatrutide and the 30% Weight Loss Frontier 🚀

0:00 4:04

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Dr RR Baliga's "Got Knowledge Doc" Podkast?

This episode is 4 minutes long.

When was this Dr RR Baliga's "Got Knowledge Doc" Podkast episode published?

This episode was published on May 25, 2026.

Can I download this Dr RR Baliga's "Got Knowledge Doc" Podkast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!